Pasithea Therapeutics Announces Conference Presentation Update
MIAMI -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), dedicated to advancing biotechnology, has made a key announcement regarding its upcoming presentation. The company, known for its innovative drug candidate PAS-004, a macrocyclic MEK inhibitor, has updated the timing for its management's live presentation at the H.C. Wainwright 27th Annual Global Investment Conference.
Updated Presentation Details
Originally scheduled for a different time, Pasithea's presentation will now take place on Monday, at 5:00 PM Eastern Time. This event will occur within the context of the conference, running from September 8-10. The conference will be held at the Lotte New York Palace Hotel.
During the presentation, CEO Dr. Tiago Reis Marques will discuss the exciting developments surrounding PAS-004 and the company’s current initiatives. In addition to the live presentation, management will be available for one-on-one meetings with interested parties throughout the event, providing an excellent opportunity for engagement.
About PAS-004
PAS-004 is at the forefront of Pasithea's ongoing clinical research, specifically targeting RASopathies, MAPK pathway-driven tumors, and various other diseases. Currently, the drug is undergoing Phase 1 clinical trials involving advanced cancer patients. This innovative treatment aims to offer new hope for patients facing challenging health conditions.
Furthermore, Pasithea is also conducting a Phase 1/1b clinical trial intended for adult patients suffering from neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas. Such trials are crucial for evaluating the safety and efficacy of PAS-004, which the company is keen to advance after thorough assessment.
Ongoing Developments
As the conference approaches, anticipation surrounding the performance of Pasithea’s drug candidate intensifies. The company is not merely presenting their findings but is also engaging with the investment community to share insights on the clinical development pathway and potential applications of PAS-004.
It is important for stakeholders to understand the significance of Pasithea's research and development efforts. With a strong focus on patient-centric outcomes, Pasithea is adamant about pushing the boundaries of conventional treatment options in biotechnology.
Frequently Asked Questions
What is the focus of Pasithea Therapeutics?
Pasithea Therapeutics is primarily centered on researching and developing innovative drug candidates, including PAS-004 for various cancers and related conditions.
When is the updated presentation time for Pasithea's conference?
The presentation will be held on September 8, at 5:00 PM Eastern Time during the H.C. Wainwright Annual Global Investment Conference.
Where will the conference take place?
The conference will be hosted at the Lotte New York Palace Hotel from September 8-10.
Who will represent Pasithea during the presentation?
Dr. Tiago Reis Marques, the CEO of Pasithea, will be delivering the live presentation.
What is PAS-004?
PAS-004 is a next-generation macrocyclic MEK inhibitor under investigation for treating RASopathies and MAPK pathway-driven tumors.
